ライフサイエンスコーパス: drug efficacy

1 owing accurate evaluation of antituberculous drug efficacy.

2 ection, and can be used to predict antiviral drug efficacy.

3 the bacterial drug tolerance and may enhance drug efficacy.

4 ical mechanism contributes to antidepressant drug efficacy.

5 in some patients, without apparent change in drug efficacy.

6 ns could significantly enhance PI3K-targeted drug efficacy.

7 bitors and evaluate the apoptosis-associated drug efficacy.

8 ify the extent to which it inflates apparent drug efficacy.

9 function as a survival mechanism that limits drug efficacy.

10 phenotype was ameliorated in accordance with drug efficacy.

11 model systems for preclinical evaluation of drug efficacy.

12 e and well-controlled studies to demonstrate drug efficacy.

13 eatic tumor patients for early assessment of drug efficacy.

14 al model suited to evaluating antimetastatic drug efficacy.

15 e used as a surrogate marker of antiatheroma drug efficacy.

16 imes, decreasing drug dosages and increasing drug efficacy.

17 it cell-specific vulnerabilities for maximum drug efficacy.

18 for varied drug metabolism, which influences drug efficacy.

19 forth the possibility of improved antitumor drug efficacy.

20 evelopment strategies, immune disorders, and drug efficacy.

21 as well as for the evaluation of antifungal drug efficacy.

22 n to disease outcome, and interpretations of drug efficacy.

23 ssessing disease progression, prognosis, and drug efficacy.

24 , treating autoimmune disease, and improving drug efficacy.

25 ns of the active forms of drugs, and thereby drug efficacy.

26 mistry and receptor conformation in defining drug efficacy.

27 intracellular delay and continuously varying drug efficacy.

28 velopment, hampering predictions of clinical drug efficacy.

29 armaceutical drugs correlate well with known drug efficacy.

30 xoid precursors for the purpose of improving drug efficacy.

31 cts on host metabolism, which contributes to drug efficacy.

32 to be only occasionally useful for studying drug efficacy.

33 nd these CRs may be the basis for changes in drug efficacy.

34 roviding a means for investigating antiviral drug efficacy.

35 ay reveal common mechanisms of antipsychotic drug efficacy.

36 ce of inter-individual variability, impacted drug efficacy.

37 imicrobial in nature, they negatively affect drug efficacy.

38 ermediate end point to assess renoprotective drug efficacy.

39 patients improve compliance and maximize the drug efficacy.

40 nity and drug residence time toward improved drug efficacy.

41 rticles into the cytoplasm ultimately limits drug efficacy.

42 tory approval but may not accurately reflect drug efficacy.

43 lower disease risk factor levels and affect drug efficacy.

44 ory previously reported to result in reduced drug efficacy.

45 lly in fish and serve as a platform to study drug efficacy.

46 how that these models can effectively assess drug efficacy.

47 examining P. vivax liver stage infection and drug efficacy.

48 phenomenon that we suggest may contribute to drug efficacy.

49 omimetic systems to study cancer biology and drug efficacy.

50 g resistance that pose as major obstacles in drug efficacy.

51 test, suggesting an age-related decrease in drug efficacy.

52 t the ITS force map can report anti-platelet drug efficacy.

53 om gene overactivation and use it to predict drug efficacy.

54 nvasive imaging of tumor pathophysiology and drug efficacy.

55 tease inhibitors are simulated using various drug efficacies.

56 primarily responsible for the differences in drug efficacies.

57 anding of the effects of gene alterations on drug efficacies.

58 They focused on (1) evidence (drug efficacy), (2) comparative performance, and (3) bar

59 type CEPs were defined for immunosuppressive drug efficacy (7 items) and for toxicity (15 items).

60 Anthelmintic drug efficacy (ADE) is generally estimated as a populati

61 nation with ivermectin would ensure improved drug efficacies against trichuriasis and strongyloidiasi

62 will greatly expand the ability to evaluate drug efficacy against gram-positive bacteria in living a

63 Studies of drug efficacy against IA and Aspergillus virulence rely

64 gh-throughput in vivo model for the study of drug efficacy against IA and Aspergillus virulence.

65 experiments are frequently used to determine drug efficacy against the survival and proliferation of

66 ssay has been optimized for determination of drug efficacy against two potentially pathogenic species

67 encing the great variation in toxicities and drug efficacy among individual patients.

68 HCV clinical trials, but large variation in drug efficacy among the various HCV genotypes has been d

69 ants who received at least one dose of study drug; efficacy analyses were by intention to treat.

70 ents who received at least one dose of study drug; efficacy analyses were done in all patients who re

71 orm could provide both an early indicator of drug efficacy and a potential molecular stratifier for h

72 zation and internalization that depends upon drug efficacy and affinity.

73 were detected and potentially contribute to drug efficacy and cardiotoxicity.

74 accurate, time-dependent, live monitoring of drug efficacy and clearance in live tumors.

75 us would be extremely valuable for assessing drug efficacy and could provide new pathophysiological i

76 otentially broad implications for bispecific drug efficacy and design.

77 s of determining the molecular substrates of drug efficacy and drug-induced adverse events.

78 one with cimetidine and vitamin E to enhance drug efficacy and frequent intramuscular administrations

79 randomized clinical trials can characterize drug efficacy and generate transcriptional, functional,

80 anti-drug Abs (ADA) that may interfere with drug efficacy and impact patient safety.

81 metabolizing enzymes, resulting in decreased drug efficacy and increased resistance.

82 nefits, allowing more accurate assessment of drug efficacy and more informed benefit-vs-risk decision

83 s, and is robust across several estimates of drug efficacy and of treatment cost.

84 In this context, drug efficacy and potency are interrelated because they

85 We incorporated published data on drug efficacy and probability of HIT-related thromboembo

86 cells and as a means of evaluating targeted drug efficacy and resistance in cancer cells.

87 erstanding of mechanisms of antitrypanosomal drug efficacy and resistance will aid the rational desig

88 might pursue a more personalized approach to drug efficacy and risk.

89 In the field of cardiac drug efficacy and safety assessment, information on drug

90 ibody (ADA) responses are a concern for both drug efficacy and safety, and high drug concentrations i

91 tical research: drug discovery and delivery, drug efficacy and safety, pharmacoepidemiology and drug

92 reening, and function in cellular assays for drug efficacy and safety.

93 ein higher order structures needed to ensure drug efficacy and safety.

94 tionized drug delivery in terms of improving drug efficacy and safety.

95 Additionally, it has been used to evaluate drug efficacy and selectivity, and to identify new targe

96 nd understanding susceptibility to diseases, drug efficacy and side effects for different populations

97 howed robust and pervasive correlations with drug efficacy and side effects in both CATIE and STAR*D.

98 says for comprehensive prediction of in vivo drug efficacy and side effects represent an actual bottl

99 her disappointing results, with low, if any, drug efficacy and significant side effects.

100 eptor binding affinity is not a guarantee of drug efficacy and that other factors, including pharmaco

101 o long-term complications, including loss of drug efficacy and the onset of dyskinesia.

102 Therapeutic drug efficacy and tolerability of memantine have been at

103 ing effective antitumor drugs, and balancing drug efficacy and toxicity are discussed.

104 Short-term drug efficacy and toxicity data have previously been pre

105 ng major diseases and the molecular basis of drug efficacy and toxicity is a fundamental problem in m

106 ma proteins is of fundamental importance for drug efficacy and toxicity studies.

107 The relative strengths of drug efficacy and toxicity that vary in human population

108 of the human gastrointestinal microbiome on drug efficacy and toxicity, there is often an incomplete

109 ronidase inhibition, which may improve human drug efficacy and toxicity.

110 s) and off-target(s), providing evidence for drug efficacy and toxicity.

111 y genetic contributors to human variation in drug efficacy and toxicity.

112 om blood to the retina and thereby influence drug efficacy and toxicity.

113 and contribute to individual differences in drug efficacy and toxicity.

114 kers for disease diagnosis and for assessing drug efficacy and toxicity.

115 interpret the growing compendium of data on drug efficacy and toxicology in patient populations.

116 analysis and offers a more direct measure of drug efficacy and treatment response, potentially provid

117 identify clinically meaningful predictors of drug efficacy and/or side-effect burden.

118 herefore be a novel determinant of antiviral drug efficacy, and could serve as a target for future an

119 for a number of protein substrates, monitor drug efficacy, and identify disease biomarkers in an ani

120 rance was therefore an unreliable measure of drug efficacy, and instead that human immunity is the pr

121 effective model for evaluating antipsychotic drug efficacy, and provides a potential mechanism to acc

122 Results were sensitive to drug price, drug efficacy, and quality of life after successful trea

123 ll be deployed in future studies of disease, drug efficacy, and toxicity to discover and identify bio

124 ate the role played by virulence attributes, drug efficacy, and vaccine candidates.

125 t relationship between infusion location and drug efficacy; animals with cannulae anterior to the PFC

126 st commonly used in studies of antipsychotic drug efficacy, antidepressant drug response, and drug-in

127 sis reveals that the observed differences in drug efficacy are in large part explained by single or d

128 roBNP changes in response to therapy predict drug efficacy are needed.

129 cological optimization had limited impact on drug efficacy as the compounds retained IC(50) values at

130 e genome with disease risk, progression, and drug efficacy, as well as for admixture mapping.

131 mental tool in cancer research, diagnostics, drug efficacy assessment, and therapeutics owing to its

132 is (RA) would be useful for RA diagnosis and drug efficacy assessment.

133 The B+C approach had more drug efficacy at lower frequencies, underscoring potenti

134 come effects on healthy tissue and increases drug efficacy at the target site.

135 , which in turn will contribute to increased drug efficacy, avoidance of adverse effects, or repositi

136 bes Project Rephetio to systematically model drug efficacy based on 755 existing treatments.

137 arasite clearance) is an indirect measure of drug efficacy because of the persistence of unviable par

138 s H2009.1 targeted liposomes fail to improve drug efficacy because the liposome drug platform prevent

139 lineate the genomic basis for differences in drug efficacy between black and white heart failure coho

140 activity, were also of potential concern in drug efficacy between the follow-on and innovator produc

141 500 cm(-1) band did not correlate well with drug efficacy but could indicate death initiation.

142 is not necessarily an indication of greater drug efficacy but rather an expected consequence of the

143 hat the viral decay rate depends not just on drug efficacy, but also on several viral infection param

144 folate transporter, RFC expression may alter drug efficacies by affecting cellular tetrahydrofolate (

145 to escort LAmB to APCs in vivo, enhanced the drug efficacy by 83% and drug APC targeting by 10-fold a

146 ored the possibility of using CLI to monitor drug efficacy by comparisons against PET.

147 nteractions of new drugs with DNA before the drug efficacy can be assessed in more expensive testing

148 Patients were monitored for drug efficacy, clinical benefit, and safety of DD.

149 In addition, drug efficacy correlated with the presence of G6 in the

150 G(1) cell cycle arrest, and cell death, with drug efficacy dependent on the levels of phosphorylated

151 en, we were unable to detect any evidence of drug efficacy despite demonstration of target engagement

152 le under a wide variety of assumptions about drug efficacy, drug cost, and rates of cardiac and cereb

153 y system research for comprehensive study of drug efficacy, drug penetration, receptor targeting, and

154 ppropriate biomarkers that aide in assessing drug efficacy during clinical trials independent of clin

155 recently introduced the notion of a critical drug efficacy, epsilon(c), such that if overall drug eff

156 g efficacy, epsilon(c), such that if overall drug efficacy, epsilon(tot), is higher than the critical

157 athematical model that includes the critical-drug efficacy (epsilonc; the efficacy required for a dru

158 n between knockout phenotype and anticipated drug efficacy, establishing an important marker for supe

159 failure (recrudescence) and to adjust final drug efficacy estimates.

160 aintenance of plasma drug concentrations and drug efficacy for almost 3 weeks after a single dose.

161 appear to be clinically useful for comparing drug efficacy for the prevention of P. vivax infection r

162 hope it not only will support translation of drug efficacy from animal models to clinical trials but

163 We investigated the possibility of assessing drug efficacy from measurements of plasma HIV-1 concentr

164 rate, so that it is not possible to extract drug efficacy from viral decay rate alone.

165 Anticancer drug efficacy has been tested on circulating tumor cells

166 recognized pharmacogenomic associations with drug efficacy have been further validated (e.g. with clo

167 gonist, have been discovered, but studies of drug efficacy have been hampered by the lack of a model

168 y, epsilon(tot), is higher than the critical drug efficacy (i.e., epsilon(tot) > epsilon(c)) then vir

169 ination of IC50 values allowed us to compare drug efficacy in 2D and 3D culture models and moreover,

170 al conditions cannot accurately reflect true drug efficacy in a patient, as a tumor is often under lo

171 are contemporary information on antimalarial-drug efficacy in all endemic regions so that decisions o

172 fter onset, and has been used to demonstrate drug efficacy in animal models of stroke.

173 rial nucleotide metabolism genes that affect drug efficacy in C. elegans.

174 would be helpful in assessing antiarrhythmic drug efficacy in children, because their results may dif

175 Real-time monitoring of drug efficacy in glioblastoma multiforme (GBM) is a majo

176 rs may have very limited value in predicting drug efficacy in human disease.

177 of preclinical tests that accurately predict drug efficacy in humans.

178 ing noninvasive monitoring of c-Myc-targeted drug efficacy in intact cells and living mice.

179 points are available to delineate antifungal drug efficacy in non-Aspergillus invasive mold infection

180 Although comparisons of drug efficacy in nonrandomized studies should be viewed

181 inical determination of drug sensitivity and drug efficacy in nucleotide triphosphatases.

182 uency assessments are unreliable, studies of drug efficacy in panic disorder have generally used redu

183 inhibition could work in concert to enhance drug efficacy in response to food restriction.

184 and dopamine receptor 2 genes may influence drug efficacy in schizophrenia.

185 employed to generate mathematical models for drug efficacy in terms of measurable physical values.

186 Optimization of drug efficacy in the brain requires understanding of the

187 toward predicting therapeutic mechanisms of drug efficacy in the setting of CPVT and then using thes

188 The implications of these results for drug efficacy in the treatment of individual patients wi

189 iduals have prevented us from achieving high drug efficacy in treating many complex diseases, includi

190 istolytica, and difficulties in quantitating drug efficacy in vitro.

191 ry parameter because it can reliably predict drug efficacy in vivo.

192 Drug efficacy is a major target of beta1-AR voltage-depe

193 or Metastatic Prostate Cancer: Evaluation of Drug Efficacy is a randomized controlled trial using a m

194 al disease (MRD) as a marker of antileukemic drug efficacy is being used to assess risk status and, i

195 ic death rate of infected cells when overall drug efficacy is close to 1.

196 ing molecular biomarkers that predict cancer drug efficacy is crucial for the advancement of precisio

197 effects and real-time in situ monitoring of drug efficacy is highly desirable for personalized medic

198 Early assessment of antiretroviral drug efficacy is important for prevention of the emergen

199 These findings indicate that drug efficacy is increased when the subcellular site of

200 lines of evidence suggest that antipsychotic drug efficacy is mediated by dopamine type 2 (D(2)) rece

201 integration with other factors relevant for drug efficacy is poorly understood.

202 required to prevent a false conclusion about drug efficacy is presented.

203 nued high efficacy of praziquantel; however, drug efficacy is rarely monitored using appropriate stat

204 ing that can be achieved by these compounds (drug efficacy) markedly differs among species homologs o

205 Antipsychotic drug efficacy may have decreased over recent decades.

206 rystal structure provides understanding of a drug efficacy mechanism related to the induction and sta

207 Anticancer drug efficacy might be leveraged by strategies to target

208 Although drug efficacy might not correlate with specificity, it w

209 D and 3D multiwell-multielectrode device for drug efficacy monitoring based on direct real-time imped

210 combinations using easily obtainable single drug efficacy, no detailed mechanistic understanding of

211 ave shown that it is possible to extract the drug efficacy of antivirals from the viral decay rate of

212 is study, to improve the tumor targeting and drug efficacy of the poorly water-soluble drug, doxorubi

213 and minimizes side effects while maximizing drug efficacy, offers a potential new approach for treat

214 ved in bone colonization and to rapidly test drug efficacies on bone micrometastases.

215 hes with the aim of predicting the impact of drug efficacy on disease progression and the persistence

216 Therefore, trials that assess drug efficacy on exacerbations are done late in clinical

217 Enhanced drug efficacy on positively supercoiled DNA is due prima

218 etic mouse model may be useful in evaluating drug efficacy on schizophrenia vulnerability.

219 discontinuations of treatment due to lack of drug efficacy or adverse events.

220 loss of free virus (P = .039) and decreased drug efficacy (P = .048), suggesting functional relevanc

221 acid substitutions can significantly affect drug efficacy prompted us to examine ligand-induced sign

222 ant strains is widened for a higher level of drug efficacy provided that the treatment is not potent

223 two-stage phase II trial, accepting a target drug efficacy rate of 20% and a rejection error of 5%.

224 sharp band at 1000 cm(-1), gave the correct drug efficacy ratio as determined by the commonly used X

225 iffness to in vivo tumor growth kinetics and drug efficacy remains elusive.

226 s did not significantly inflate estimates of drug efficacy, reporting biases led to significant incre

227 es for cell phenotypic behaviors involved in drug efficacy responses.

228 improved drug delivery methods that increase drug efficacy, safety and patient compliance.

229 ug discovery and provide novel platforms for drug efficacy screens.

230 n animals, CRD has been employed to evaluate drug efficacy, strain, sex or genetic differences and ch

231 Drug efficacy strongly depends on the presence of the dr

232 Current drug efficacy studies focus on reducing leukemia cell bu

233 the study of chronic biofilm infections and drug efficacy studies in vivo.

234 se devices in the drug discovery process and drug efficacy studies.

235 rther, we define and characterize a critical drug efficacy, such that for efficacies above the critic

236 trate the usefulness of our model/method for drug efficacy testing, we examined the effect of CTLA4-I

237 cer diagnosis, therapeutic applications, and drug efficacy tests.

238 circuit, are taken into account in deciding drug efficacy, thereby mapping each malfunction to an ap

239 tal study or broaden the generalizability of drug efficacy through a preplanned meta-analysis.

240 y with rate control and anticoagulation, but drug efficacy to control rate remains uncertain.

241 ct and real-time measurements of bevacizumab drug efficacy to the VEGF-VEGFR angiogenic switch in liv

242 sformative potential for in vitro testing of drug efficacy towards prediction of in vivo outcomes and

243 o disease sites significantly contributes to drug efficacy, toxicity and clearance.

244 of differences in incidence rates as well as drug efficacy, toxicity, and costs, the role of differen

245 ribe a systematic study of nitroheterocyclic drug efficacy using highly sensitive bioluminescence ima

246 to explore the possibility of extracting NAI drug efficacy using only the observed viral titer decay

247 pan-cancer cell lines, accurately predicted drug efficacy using the driver genes and their seeded ge

248 Drug efficacy was assessed on a modified intention-to-tr

249 Decreased drug efficacy was due primarily to a drop in baseline (i

250 Drug efficacy was evaluated by changes in maximal treadm

251 Drug efficacy was evaluated by retinal histologic analys

252 Drug efficacy was evaluated over 2 wk using (18)F-FDG sm

253 Drug efficacy was evaluated with magnetic resonance imag

254 However, drug efficacy was greatest in subjects with low Spd:Spm

255 ing seemed to reduce predicted toxicity, and drug efficacy was maintained.

256 urs of the boys' afternoon dose, testing for drug efficacy was performed by using objective measures

257 Drug efficacy was tested by measuring muscle strength ma

258 , even with the simplification of a constant drug efficacy, we show that the viral decay rate depends

259 oteins provides a new approach for improving drug efficacy while mitigating side effects.

260 Correct folding of a mAb is critical for drug efficacy, while misfolding can impact safety by eli

261 Measurement of antiplatelet drug efficacy with a point-of-care device and alternativ

262 d drug block with high [K+]o include loss of drug efficacy with ischemia and with rapid pacing; the l